Physician profile
Larry Marshall
NPI 1114018132
$3,474.58
in general payments reported to CMS, 2019-2025
27 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $771 · 2021: $858 · 2022: $410 · 2023: $487 · 2024: $302 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $870.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $608.27 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $390.23 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $342.05 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $192.71 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $192.29 | 2022-2024 | Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $123.41 | 2021-2023 | |
| Boston Scientific Corporation | $120.38 | 2023-2025 | Versacross Access Solution, Watchman Access System, Watchman |
| Glaxosmithkline, LLC. | $86.70 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $56.40 | 2020-2021 | |
| Amarin Pharma, INC. | $56.01 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $52.45 | 2024-2025 | Zoryve, Livalo |
| Novartis Pharmaceuticals Corporation | $46.34 | 2020-2022 | |
| Amgen INC. | $43.05 | 2023-2025 | Otezla, Repatha, Otezla |
| Horizon Therapeutics Plc | $42.72 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $38.47 | 2020 | |
| Merck Sharp & Dohme LLC | $35.39 | 2019-2023 | Steglatro, Belsomra |
| Neotract INC. | $24.01 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.14 | 2023 | Gvoke Hypopen |
| Edwards Lifesciences Corporation | $20.94 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Idorsia Pharmaceuticals US INC | $18.16 | 2023 | Quviviq |
| Abbott Laboratories | $17.37 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.10 | 2022 | |
| Eisai INC. | $16.23 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.31 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.27 | 2023 | Austedo |
| E.R. Squibb & Sons, L.L.C. | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.